Comment Re: People Underestimate COVID damage (Score 5, Informative) 163
- In the Lungs: Early autopsy and high-resolution imaging data confirmed that severe respiratory failure wasn't just caused by typical ARDS cellular damage, but by pulmonary microvascular thrombosis cutting off gas exchange entirely.
- In the Brain: Beyond macrovascular ischemic strokes, microthrombi in the cerebral microvasculature compromised the blood-brain barrier. This resulted in diffuse micro-bleeds, localized hypoperfusion, and intense neuroinflammation, which directly correlates with the severe acute encephalopathy and persistent cognitive deficits observed clinically.
The shift away from high rates of severe, widespread microvascular clotting occurred primarily between late 2021 and early 2022, driven by the sequential arrivals of the Delta and Omicron variants alongside widespread population immunity. While early-wave infections frequently presented as a devastating systemic clotting disorder, a multi-phase transition drastically reduced both the incidence and scale of thrombotic complications. [1], [2], [3], [4] Phase 1: Mid-2021 (The Delta Wave & Early Vaccination) By the time the Delta variant became dominant in the summer of 2021, mass vaccination campaigns had significantly altered clinical presentation. [3], [5]
- 70%+ Risk Reduction: Large clinical cohorts showed that vaccinated individuals who experienced breakthrough infections had up a 72% reduction in venous thromboembolism (VTE) risk compared to unvaccinated patients. [6]
- Matured Hospital Protocols: By mid-2021, frontline clinicians had abandoned early mechanical ventilation strategies in favor of aggressive, early prophylactic anticoagulation protocols (using low-molecular-weight heparin) upon patient admission, halting the progression of microthrombi before they could overwhelm the vascular bed.
Phase 2: Early 2022 (The Omicron Shift) The true evolutionary tipping point for how the virus interacted with human blood vessels arrived with the Omicron variant in late 2021 and early 2022. [4]
- Altered Tissue Tropism: Omicron shifted its primary entry mechanism. It focused its infection heavily on the upper respiratory tract rather than the deep, ACE2-rich endothelial cells of the lower lungs. This change largely spared the pulmonary microvasculature from direct endothelial invasion (endotheliitis). [2], [4]
- Fewer Central Clots: Multicenter radiology audits tracking pulmonary embolisms noted a distinct structural change during Omicron. The massive, life-threatening "saddle" or central large-vessel filling defects highly prevalent in 2020 transitioned mostly to isolated peripheral, small subsegmental clots that carried a much lower mortality rate. [4]
The Baseline Today While the acute risk of widespread microvascular collapse has fundamentally stabilized, the virus has not completely lost its thrombogenic edge. Large database reviews, including studies tracked by the CDC, confirm that patients diagnosed with COVID-19 still experience a roughly 73% increased risk of a thrombotic event in the year following their illness when compared to patients infected with other acute respiratory infections like influenza. The difference today is that the risk is an incremental, post-acute vascular vulnerability rather than the catastrophic, acute microvascular clotting that defined the pre-vaccine era. [7], [8] References:
- PMC10123679 (Early Wave Autopsy/Imaging Data)
- ASH Clinical News (New Strains & VTE Risk)
- PMC9188439 (Delta & Vaccination Clinical Cohorts)
- PMC12453200 (Omicron Radiological Audits)
- BBC News (UK Population Immunity & Variant Shifting)
- CIDRAP (Vaccine VTE Risk Reduction Study)
- Open Forum Infectious Diseases (Post-Acute Vascular Vulnerability)
- CDC Emerging Infectious Diseases (COVID-19 vs Influenza Thrombotic Risk)